The Effectiveness of Dry Needling Treatment in Patients Diagnosed With Dorsal Myofascial Pain Syndrome.

Launched by KUTAHYA HEALTH SCIENCES UNIVERSITY · Mar 24, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the effectiveness of a treatment called dry needling for patients suffering from dorsal myofascial pain syndrome, which is a type of back pain often caused by sensitive muscle areas in the upper back. The trial aims to see if dry needling, a technique that involves inserting thin needles into specific muscle points to relieve pain, can help improve symptoms for people with significant shoulder pain.

To be eligible for the study, participants need to be diagnosed with dorsal myofascial pain syndrome and have a pain score of 6 or higher on a scale where 0 means no pain and 10 means the worst pain possible. They must also be able to read and write. However, certain individuals, such as those with a history of back surgery or specific medical conditions, will not be able to participate. During the trial, participants will receive either the real treatment or a placebo (a treatment that looks the same but doesn’t contain any active ingredients) without knowing which one they are getting. This helps ensure that the results are reliable. Overall, this study could provide important information on how effective dry needling is for managing this type of pain.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Clinically diagnosed with Dorsal Myofascial Pain Syndrome associated with rhomboid and trapezius trigger point.
• • Having a shoulder pain Visual Analog Scale (VAS) score of 6 or higher.
• • Ability to read and write
• Exclusion Criteria:
• • History of spinal surgery.
• • Lesions, atrophy, or scars in the skin around the back.
• • Undergoing physiotherapy targeting the back and lumbar region in the last 6 months.
• • Undergoing an interventional procedure for back or lumbar pain in the last 3 months.
• • Use of steroids in the last 1 month.
• • Special conditions such as epilepsy, pregnancy, injection phobia, etc.
• • Inability to comply with the restriction on the use of steroid and non-steroidal anti-inflammatory drugs during the treatment period.